Suspension of trading
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.07B 6.5B 6.12B 11.49B 773B 11.59B 76.99B 29.98B 379B 30.74B 30.09B 1,313B | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.47B 5.95B 5.6B 10.52B 707B 10.6B 70.46B 27.43B 347B 28.13B 27.53B 1,201B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 12.01 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Reents
PSD | President | 59 | 01/08/2024 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
Scott Reents
BRD | Director/Board Member | 59 | 01/08/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | General Counsel | 433,824 | 0.2381% | ||
| 01/08/24 | Issuer sale | Chief Financial Officer | 222,146 | 0.1219% | ||
| 01/08/24 | Issuer sale | Director | 154,118 | 0.0846% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +32.20% | 8.19B | |
| +3.23% | +2.93% | +61.50% | +113.87% | 54.54B | |
| +0.04% | +5.05% | +43.44% | +36.75% | 43.86B | |
| +3.04% | +7.05% | -12.15% | -16.12% | 22.63B | |
| +3.07% | +7.15% | -1.82% | +387.14% | 20.7B | |
| -0.53% | -0.27% | +12.68% | -37.07% | 15.84B | |
| +5.27% | +1.71% | +11.09% | -38.81% | 14.83B | |
| +0.65% | -0.27% | +26.80% | +176.87% | 13.1B | |
| -5.17% | +4.13% | +13.12% | - | 12.66B | |
| -0.27% | +6.06% | +78.78% | +103.63% | 11.56B | |
| Average | +1.01% | +0.16% | +23.34% | +84.27% | 21.79B | |
| Weighted average by Cap. | +1.50% | +0.17% | +30.93% | +88.13% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -303M -279M -262M -493M -33.17B -497M -3.3B -1.29B -16.28B -1.32B -1.29B -56.32B | -433M -373M -343M -323M -607M -40.85B -612M -4.07B -1.58B -20.05B -1.62B -1.59B -69.35B |
| Net Debt | -523M -451M -415M -391M -734M -49.38B -740M -4.92B -1.91B -24.23B -1.96B -1.92B -83.84B | -695M -600M -552M -519M -976M -65.63B -984M -6.54B -2.54B -32.21B -2.61B -2.55B -111B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
